RNAC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

100.22K

-113.2%

-0.866

+45.88%

125.00K

-88.64%

-0.860

+32.31%

125.00K

-58.05%

-0.834

-266.8%

Estimates Revision

The market is revising Upward the revenue expectations for Cartesian Therapeutics, Inc. (RNAC) for FY2025, with the revenue forecasts being adjusted by 5.74% over the past three months. During the same period, the stock price has changed by -12.02%.

Revenue Estimates for FY2025

Revise Upward

+5.74%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+17.54%

In Past 3 Month

Stock Price

Go Down

-12.02%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast RNAC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNAC is 34.67 USD with a low forecast of 16.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

16.00

Averages

34.67

High

44.00

Current: 0.000

Low

16.00

Averages

34.67

High

44.00

H.C. Wainwright

Buy

downgrade

$40 -> $30

2025-11-19

Reason

H.C. Wainwright

Price Target

$40 -> $30

2025-11-19

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Cartesian Therapeutics to $30 from $40 and keeps a Buy rating on the shares. The firm says Cartesian one of the most "mispriced assets" it has "seen in years." It is "highly unusual for a registration-aligned Phase 3 program with high likelihood of approvability to trade" at a $50M enterprise value, the analyst tells investors in a research note. H.C. Wainwright says that with 100,000 myasthenia gravis patients in the domestic population and a market "rapidly shifting to immunology agents that offer durable disease control," it sees Cartesian's current valuation as "disproportionate to the commercial opportunity and the degree of clinical risk-mitigation."

BTIG

Buy

maintain

$42 -> $44

2025-11-14

Reason

BTIG

Price Target

$42 -> $44

2025-11-14

maintain

Buy

Reason

BTIG raised the firm's price target on Cartesian Therapeutics to $44 from $42 and keeps a Buy rating on the shares. The firm cites the company's positive results disclosed from the Phase 2 trial of Descartes-08 in systemic lupus erythematosus, or SLE, showing a 100% lupus low disease activity state response and 67% disease remission, the analyst tells investors in a research note. Following these Phase 2 results, the company plans to pause development of Descartes-08 in SLE and shift focus to initiating a Phase 2 trial in myositis, with strong mechanistic alignment based on SLE and MG clinical data, the firm added.

Wedbush

NULL -> Outperform

initiated

$38

2025-07-09

Reason

Wedbush

Price Target

$38

2025-07-09

initiated

NULL -> Outperform

Reason

Wedbush initiated coverage of Cartesian Therapeutics with an Outperform rating and $38 price target.

Wedbush

Outperform

initiated

$38

2025-07-09

Reason

Wedbush

Price Target

$38

2025-07-09

initiated

Outperform

Reason

As previously reported, Wedbush initiated coverage of Cartesian Therapeutics with an Outperform rating and $38 price target. With no conditioning requirement, re-dosing capabilities, and an ongoing Phase 3 trial, the firm believes Cartesian Therapeutics could be the first cell therapy company to achieve widespread use in autoimmune diseases. Wedbush notes that a Phase 2 trial in myasthenia gravis yielded deeper responses than benchmarks for approved biologics, and a registrational Phase 3 trial is enrolling. Further upside is possible from expansion into other autoimmune indications. A Phase 2 trial in lupus will have initial data in the second half of 2025, while a Phase 2 pediatric basket trial is enrolling across multiple indications.

Mizuho

Outperform

maintain

$40

2025-05-12

Reason

Mizuho

Price Target

$40

2025-05-12

maintain

Outperform

Reason

Mizuho reiterates an Outperform rating on Cartesian Therapeutics with a $40 price target following the Q1 report. The quarter was "straightforward" with the company continuing to execute as planned, the analyst tells investors in a research note. The firm believes Cartesian shares have been "unduly punished" with other cell therapy companies due to concerns about potential changes in regulatory standards under new Center for Biologics Evaluation and Research, director Dr. Vinay Prasad. Cartesian has limited near-term FDA exposure, as the company already has a Special Protocol Assessment agreement on the registrational Phase 3 AURORA trial, Mizuho points out. Further, the firm believes the Phase 3 design should meet Dr. Prasad's more rigorous standards, given it is a placebo-controlled trial. Thus, it sees an "attractive buying opportunity" with Cartesian trading below $10 given Descartes-08's "potential blockbuster opportunity" in myasthenia gravis.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$40

2025-04-09

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$40

2025-04-09

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Cartesian Therapeutics Inc (RNAC.O) is -1.99, compared to its 5-year average forward P/E of -5.55. For a more detailed relative valuation and DCF analysis to assess Cartesian Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.55

Current PE

-1.99

Overvalued PE

-0.81

Undervalued PE

-10.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.24

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.08

Undervalued EV/EBITDA

-3.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

167.58

Current PS

369.92

Overvalued PS

365.04

Undervalued PS

-29.87

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RNAC News & Events

Events Timeline

No data

News

9.0

01-09Globenewswire

Cartesian Advances Descartes-08 Clinical Trials for Autoimmune Diseases

9.0

01-09Newsfilter

Cartesian Advances Descartes-08 Clinical Trials for Autoimmune Diseases

9.0

01-06Benzinga

Johnson & Johnson Reports Positive Phase 2b Results for Lupus Drug Nipocalimab, Plans Phase 3 Trial

People Also Watch

Frequently Asked Questions

What is Cartesian Therapeutics Inc (RNAC) stock price today?

The current price of RNAC is 8.2 USD — it has increased 0.99 % in the last trading day.

What is Cartesian Therapeutics Inc (RNAC)'s business?

Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.

What is the price predicton of RNAC Stock?

What is Cartesian Therapeutics Inc (RNAC)'s revenue for the last quarter?

Cartesian Therapeutics Inc revenue for the last quarter amounts to 452.00K USD, increased 16.80 % YoY.

What is Cartesian Therapeutics Inc (RNAC)'s earnings per share (EPS) for the last quarter?

Cartesian Therapeutics Inc. EPS for the last quarter amounts to -1.38 USD, increased 22.12 % YoY.

What changes have occurred in the market's expectations for Cartesian Therapeutics Inc (RNAC)'s fundamentals?

How many employees does Cartesian Therapeutics Inc (RNAC). have?

Cartesian Therapeutics Inc (RNAC) has 66 emplpoyees as of January 10 2026.

What is Cartesian Therapeutics Inc (RNAC) market cap?

Today RNAC has the market capitalization of 213.23M USD.